Evidence map›Paper›PMID 29221946›Full record

ArticleAtencion primaria2018

[Facing a dilemma in elderly complex and vulnerable patients: to stop or not to stop prevention?]

Laura Llobet Vila, Josep Maria Manresa Domínguez, José Manuel Carmona Segado, Alícia Franzi Sisó, Rosa Vallès Balasch, Isabel Martínez Díaz

Abstract readMulticenter Study
In one paragraph

Article in Atencion primaria, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Laura Llobet VilaABS Castellar del Vallès, Institut Català de la Salut, Castellar del Vallès, Barcelona, España; Unitat de Suport a la Recerca Metropolitana Nord, IDIAP Jordi Gol, Sabadell, Barcelona, España. Electronic address: llobetvila@gmail.com.
Josep Maria Manresa DomínguezUnitat de Suport a la Recerca Metropolitana Nord, IDIAP Jordi Gol, Sabadell, Barcelona, España; Departament de Infermeria, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Barcelona, España.
José Manuel Carmona SegadoABS Sant Llorenç Savall, Institut Català de la Salut, Sant Llorenç Savall, Barcelona, España.
Alícia Franzi SisóUnitat de Farmàcia, SAP Vallès Occidental, Institut Català de la Salut, Sabadell, Barcelona, España.
Rosa Vallès BalaschABS Castellar del Vallès, Institut Català de la Salut, Castellar del Vallès, Barcelona, España.
Isabel Martínez DíazABS Castellar del Vallès, Institut Català de la Salut, Castellar del Vallès, Barcelona, España.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectives1-To know the preventive prescription (statin, antiplatelet drugs, bisphosphonates, calcium and vitamin D and Vit B12) of elderly patients previously identified as a CCD (with a complex chronic disease) and ACD (with advanced chronic disease and lifetime expectancy of less than 12 months) who died during 2015. 2-To assess the correct indication of Proton Pump Inhibitors (PPI) to determine potentially avoidable medication.

designRetrospective observational study. LOCATION: Four Primary Health Centres, Castellar del Vallès (Barcelona).

participants128 patients, 70 ACD and 58 PCC. MAIN MEASUREMENTS: Number of drugs at the time of death from the 6 selected group, deprescription (6 months prior to death due to advanced chronic disease), primary or secondary prevention and inappropriate prescription of PPI.

resultsAverage age of 85'3 years (10,3). 40% took an antiplatelet drug, avoidable in 60% of the ACD, since they did not present any previous cardiovascular episode. 20% of the patients took statins, in which 48% of the cases were primary prevention. The PPI prescription was 67% with inadequate indication for use in 49% of these cases. 20% took calcium / Vitamin D and 1,6% of the ACD a bisphosphonate. There was a 16% deprescription.

conclusionsA high percentage of our patients with advanced chronic disease and short life expectancy still continue to take preventive and avoidable treatments, potentially dangerous due to their side effects. There is a need to reflect on what we do with these vulnerable patients.

Indexed as

Chronic DiseaseDeprescriptionsPrimary PreventionSecondary PreventionAged, 80 and overCross-Sectional StudiesHumansPrescription DrugsRetrospective StudiesSeverity of Illness IndexPrescription DrugsDeprescriptionDesprescripciónInappropriate Prescribing'sPatient safetyPrescripciones inadecuadasSeguridad del paciente

Identifiers

PMID29221946
PMCPMC6837059

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.